



**ROQUEFORT**  
INVESTMENTS PLC

# INVESTOR PRESENTATION

March 2021

# Disclaimer



**NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, JAPAN, OR THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO.**

This presentation is the sole responsibility of the directors of Roquefort Investments plc (“**Roquefort**” or the “**Company**”) and does not constitute an offer or invitation for the sale or purchase of any securities, nor does it, nor does it purport to, set out or refer to all or any of the information an investor might require or expect in making a decision as to whether or not to deal in securities in the Company. This presentation does not constitute a recommendation regarding the securities of the Company nor a representation that any dealing in those securities is appropriate. The Company accepts no duty of care whatsoever to the reader of this presentation in respect of its contents and the Company is not acting in any fiduciary capacity.

The information contained in this presentation is being supplied to a very limited number of persons for information purposes only. In the United Kingdom, this presentation is directed at, and is only being made available to, persons in the United Kingdom who are qualified investors within the meaning of Article 2(e) of the Prospectus Regulation (Regulation 2017/1129) as applicable in the United Kingdom and as amended by the Prospectus (Amendment etc) (EU Exit) Regulations 2019 (SI2019/1234) and who are (a) persons who have professional experience in matters relating to investments and who fall within the category of person set out in Article 19 of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “**Order**”) or (b) persons to whom Article 49(2) of the Order applies, being high net worth companies, unincorporated associations, partnerships or trusts or their respective directors, officers or employees as described in Article 49 of the Financial Promotion Order. In Australia this presentation is directed at, and is only being made available to, person who satisfy the requirement in order to be classified as “sophisticated investors”, “experienced” and “professional investors” (as defined in section 708(8), 708(10) and 708(11) of the Australian Corporations Act 2001 (Cth)).

No offer or invitation or solicitation of any offer to acquire securities of the Company is being made now nor does this presentation constitute or form part of any invitation or inducement to engage in investment activity under section 21 of the Financial Services and Markets Act 2000 (“**FSMA**”). This presentation is not an approved prospectus or other equivalent offering document under the securities laws of any jurisdiction. Neither this presentation, its contents, nor any part thereof have been approved (for the purposes of section 21 of FSMA) by an authorised person within the meaning of FSMA. Reliance on this presentation for the purposes of engaging in any investment activity may expose an individual to a significant risk of losing all the assets invested.

No reliance may be placed for any purpose whatsoever on the information contained in this presentation or any assumptions made as to its completeness and no warranty or representation is given by or on behalf of the Company nor its directors, employees, agents and advisers as to the accuracy or completeness of the information or opinions contained in this presentation and no liability is accepted by any of them for any such information or opinions, provided that nothing in this paragraph shall exclude liability for any representation or warranty made fraudulently. The information and opinions contained in this presentation are provided as at the date hereof.

By accepting or electronically accessing this presentation, the recipient represents, warrants and undertakes to the Company that they (a) are a person who falls within the above description of persons entitled to receive the presentation (b) will not forward the presentation to any other person, or reproduce or publish this document, in whole or in part, for any purpose and (c) have read and agree to comply with the contents of this notice. The recipient further agrees to return to the Company, upon request, all documents and other material held by it relating to the project referred to in the presentation.

This presentation is being delivered to interested parties for information only and upon the express understanding that such recipients will use it only for the purpose set out above. Neither the issue of this presentation nor any part of its contents is to be taken as any form of commitment on the part of the Company to proceed with any transaction and the right is reserved to terminate any discussions or negotiations with any prospective investors. In no circumstances will the Company be responsible for any costs, losses or expenses incurred in connection with any appraisal or investigation of the Company.

The contents of this presentation are confidential and must not be copied, published, reproduced, distributed or passed in whole or in part to others at any time by recipients. This presentation is being provided to recipients on the basis that they keep confidential any information contained herein or otherwise made available, whether oral or in writing, in connection with the Company.

In particular, this presentation should not be distributed, published or reproduced in whole or in part or disclosed by recipients to any other person or entity and, in particular, should not be distributed to United States residents, corporations, or other entities, US persons (as defined in Regulation S promulgated under the United States Securities Act of 1933 (as amended)), persons with addresses in the United States of America (or any of its territories or possessions), Canada, Japan, the Republic of Ireland, the Republic of South Africa or Australia, or to any corporation, partnership or other entity created or organised under the laws thereof, or in any other country outside the United Kingdom where such distribution may lead to a breach of any law or regulatory requirement. Notwithstanding the foregoing, the Company can distribute this document to US Persons (as defined above), persons with addresses in the United States of America (or its territories or possessions), United States residents, corporations or other entities if the Company is satisfied that an applicable exemption applies. Distribution of this document in the United States of America in the absence of such an applicable exemption may constitute a violation of United States securities law.

By accepting a copy of the presentation you agree to be bound by the foregoing provisions.

## **Forward-looking Statements**

This presentation may contain forward-looking statements. These statements relate to the future prospects, developments and business strategies of the Company and its subsidiaries (the “**Group**”). Forward-looking statements are identified by the use of such terms as “believe”, “could”, “envisage”, “estimate”, “potential”, “intend”, “may”, “plan”, “will” or the negative of those, variations or comparable expressions, including references to assumptions. The forward-looking statements contained in the presentation are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by those statements. If one or more of these risks or uncertainties materialises, or if underlying assumptions prove incorrect, the Group’s actual results may vary materially from those expected, estimated or projected. Given these risks and uncertainties, potential investors should not place any reliance on forward-looking statements. These forward-looking statements speak only as at the date of the presentation.

# Overview




- Roquefort Investments plc was incorporated in August 2020
- Highly experienced Board with proven track record in bringing companies to market and completing value accretive transactions
- Listing on the London Stock Exchange (Standard List) in March 2021 (ROQ)
- Raising up to £1 million at 5p per share
- Post IPO will be seeking to acquire an early stage business in the medical biotechnology sector



# Strategy



- Roquefort Investments is seeking to acquire an early stage business in the medical biotechnology sector
- Suitable acquisition targets will be identified through the Board's network in the UK, Continental Europe and Australia
- To pursue opportunities to acquire biotech business focused on early stage opportunities in the medical biotech sector
- Aiming to complete a suitable acquisition in 2021



# Board of Directors / Founders



## **Stephen West:** Executive Chairman

- over 26 years of financial and corporate experience gained in public practice, oil and gas, mining and investment banking spanning Australia, UK, Europe, CIS and Africa
- Fellow Chartered Accountant (Australia) and Chartered Accountant (England & Wales), with Bachelor of Commerce (Accounting and Business Law)
- proven track record in working with growth companies, particularly in the resource sector, with extensive experience in IPOs, secondary listings, corporate finance, fundraisings, investor relations and financial and management reporting
- currently CFO/executive director at AIM listed Advance Energy plc and non-exec Chairman of Zeta Petroleum plc

## **Dr Mark Rollins:** Non-Executive Director

- doctorate in Engineering Science from Oxford University and a Masters in Mathematics from Cambridge University
- has held senior positions at several large listed companies including Chairman and CEO of Ukrnafta in Ukraine with over 20,000 employees, and Senior VP at BG Group plc and Shell International
- Proven commercial track record with extensive experience in business development, government negotiation and private equity
- currently non-exec Chairman of Advance Energy plc

## **Dr Michael Stein:** Director Designate<sup>+</sup>

- medical doctor (Honours) and biochemist (First Class Honours) from the University of Cape Town (1988) and from the University of Oxford (Rhodes Scholar) with a doctorate in Physiological Sciences (Immunology)
- a business leader and strategic adviser with C-suite experience in healthcare including being founding CEO of Valo Therapeutics and OxStem Ltd, an award-winning biotechnology spin-out from the University of Oxford, which broke the UK record for a seed round fund-raise of over £16m in May 2016
- founder and former CEO for Doctor Care Anywhere, acquired by Synergix in 2015. In 2001, he co-founded the Map of Medicine Ltd (the Map) with University College London. As founding CEO (and later CMO), the Map was nationally licensed across NHS England (2005-15) and acquired by Hearst Business Media (HBM) in 2008.

## **Glenn Whiddon:** Non-Executive Director

- extensive background in equity capital markets, banking and corporate advisory
- holds a degree in Economics from Macquarie University and has extensive corporate and management experience
- currently Director of a number of Australian and international public listed companies

*\*to be appointed a director at IPO date*

# The Biotechnology Sector



- Science-driven industry sector that makes use of living organisms and molecular biology to produce healthcare-related products and therapeutics, or to run processes
- Best known for its increasingly important role in the fields of medicine and pharmaceuticals
- Biotechnology was enjoying a golden age even before COVID-19 hit; however, the pandemic has further highlighted the crucial role this sector plays in global health – and confirms its strategic importance over the long-term
- Rapid progress in our understanding of the molecular and genetic bases of life is unleashing extraordinary new opportunities
- Many of biotechnology's products have already transformed our world and they will continue to do so beyond 2020
- Record levels of private and public investment into biotech over the last decade and the sector also enjoys strong government support in many countries



# Capital Structure




	Cash £'m	Number	%
<b>SHARES</b>			
Directors & founders	0.12	12,400,000	38%
IPO	1.00	20,000,000	62%
Costs <sup>+</sup>	(0.18)	-	-
<b>TOTAL</b>	<b>0.94</b>	<b>32,400,000</b>	<b>100%</b>
<b>WARRANTS</b>			
Seed & founders (10p)		12,000,000	
1 for 2 IPO Warrants (10p)		10,000,000	
Broker Warrants (1p)		1,500,000	
Broker Placing Warrants (10p) <sup>++</sup>		480,000	
Director Warrants (50% 5p /50% 10P)		1,500,000	
<b>TOTAL</b>		<b>25,480,000</b>	

<sup>+</sup>assuming full £1 million is raised and total costs to date of IPO of £185k (including 6% broker commission)  
<sup>++</sup> broker placing warrants equal to 6% of total shares placed by the broker (assumed to be 8 million shares)

# Pathway to Listing and Beyond



- Advisers appointed to manage the listing process
- Prospectus lodged with UKLA
- IPO fundraising being undertaken in March 2021
- Expected to list on Standard List of London Stock Exchange in March 2021 (ticker ROQ)
- Target a suitable acquisition (RTO) in 2021



[www.roquefortinvest.com](http://www.roquefortinvest.com)

“Big results require big ambitions”

Heraclitus

